secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001104659-25-051050
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma holds 2025 annual meeting, elects directors, ratifies auditor, approves say-on-pay
--------------------------------------------------------------------------------

- Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.
- Ratification of Ernst & Young as auditor for FY2025 approved: 45,165,816 for, 578,070 against.
- Advisory say-on-pay resolution approved: 30,154,992 for, 374,257 against, 9,536,311 abstain.
- Quorum of 45,746,079 shares (91.5% outstanding) present at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925051050/0001104659-25-051050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925051050/tm2515715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-051050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer